Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation

[1]  P. Boor,et al.  Vascular medial hyperplasia following chronic, intermittent exposure to 4,4′-methylenedianiline , 2007, Cardiovascular Toxicology.

[2]  Ken-ichi Isobe,et al.  An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells , 2003, Journal of neuroscience research.

[3]  V. Borutaite,et al.  Serial Review: Nitric Oxide in Mitochondria Guest Editors: Christoph Richter and Matthias Schweizer NITRIC OXIDE INHIBITION OF MITOCHONDRIAL RESPIRATION AND ITS ROLE IN CELL DEATH , 2002 .

[4]  M. Humbert,et al.  Primary pulmonary hypertension: Current therapy. , 2002, Progress in cardiovascular diseases.

[5]  A. Tanswell,et al.  Thromboxane A(2) receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase-independent mechanism. , 2002, American journal of respiratory and critical care medicine.

[6]  G. Riegger,et al.  Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension. , 2002, Cardiovascular research.

[7]  長岡 鉄太郎.  Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats , 2002 .

[8]  C. Solas,et al.  High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. , 2002, Journal of acquired immune deficiency syndromes.

[9]  Y. Kakinuma,et al.  Endothelin-1 Production Is Enhanced by Rotenone, a Mitochondrial Complex I Inhibitor, in Cultured Rat Cardiomyocytes , 2001, Journal of cardiovascular pharmacology.

[10]  R. Speich,et al.  Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.

[11]  N. Petrosillo,et al.  Pathogenesis of HIV‐Related Pulmonary Hypertension , 2001, Annals of the New York Academy of Sciences.

[12]  S. Lipshultz,et al.  HIV-associated cardiovascular complications: a new challenge for emergency physicians. , 2001, The American journal of emergency medicine.

[13]  S. Lipshultz,et al.  Pathogenesis of HIV‐Associated Cardiomyopathy , 2001, Annals of the New York Academy of Sciences.

[14]  S. Lipshultz,et al.  Pathogenesis of HIV-associated cardiovascular complications. , 2001, The Lancet. Infectious diseases.

[15]  M. Yanagisawa,et al.  Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[16]  C. Katlama,et al.  A Comparison of the Steady‐State Pharmacokinetics and Safety of Abacavir, Lamivudine, and Zidovudine Taken as a Triple Combination Tablet and as Abacavir plus a Lamivudine‐Zidovudine Double Combination Tablet by HIV‐1‐Infected Adults , 2001, Pharmacotherapy.

[17]  I. Khan,et al.  HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.

[18]  K. McMartin,et al.  Toxicity of Ethylene Glycol Metabolites in Normal Human Kidney Cells , 2000, Annals of the New York Academy of Sciences.

[19]  R. Raddino,et al.  Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. , 2000, The Journal of infection.

[20]  M. Kotler,et al.  Cardiac manifestations of acquired immunodeficiency syndrome. , 2000, Archives of internal medicine.

[21]  J. Kelley,et al.  The effects of HIV infection on endothelial function. , 2000, Endothelium : journal of endothelial cell research.

[22]  Y. Kakinuma,et al.  Mitochondrial dysfunction increases expression of endothelin-1 and induces apoptosis through caspase-3 activation in rat cardiomyocytes in vitro. , 2000, Journal of cardiovascular pharmacology.

[23]  P. Cacoub,et al.  Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. , 1999, Cardiovascular research.

[24]  T. Warner.  RELATIONSHIPS BETWEEN THE ENDOTHELIN AND NITRIC OXIDE PATHWAYS , 1999, Clinical and experimental pharmacology & physiology.

[25]  B. Reichart,et al.  Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic interventions. , 1998, Atherosclerosis.

[26]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[27]  H. Shimokawa.  Endothelial dysfunction in hypertension. , 1998, Journal of atherosclerosis and thrombosis.

[28]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[29]  D. Granger,et al.  Endothelial cell monolayers as a tool for studying microvascular pathophysiology. , 1997, The American journal of physiology.

[30]  G. Barlovatz-Meimon,et al.  Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells , 1997, Journal of the Neurological Sciences.

[31]  E. Schiffrin.  Endothelin, role in hypertension and vascular hypertrophy , 1997 .

[32]  M. Zamora,et al.  Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats. , 1996, The American journal of physiology.

[33]  C. Cooper,et al.  Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase , 1994, FEBS letters.

[34]  K. McMartin,et al.  Acute toxicity of propylene glycol: an assessment using cultured proximal tubule cells of human origin. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[35]  E. Dempsey,et al.  BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. , 1993, American journal of respiratory cell and molecular biology.

[36]  J. Coligan,et al.  Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.

[37]  R. Rothlein,et al.  Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. , 1992, The American journal of physiology.

[38]  H. Palevsky,et al.  Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.

[39]  E. Nabel,et al.  Biology of the impaired endothelium. , 1991, The American journal of cardiology.

[40]  A. Kolk,et al.  Measurement of antigen specific lymphocyte proliferation using 5-bromo-deoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation. , 1991, Journal of immunological methods.

[41]  蓮沼 紀一.  Endothelin 1 causes pulmonary vasodilation in rats , 1991 .

[42]  M. Sherrid,et al.  Primary pulmonary hypertension associated with human immunodeficiency viral infection. , 1990 .

[43]  M. Cheitlin,et al.  Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. , 1989, The American journal of cardiology.

[44]  J. Vane,et al.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Driscol,et al.  Primary pulmonary hypertension in patients with classic hemophilia. , 1988, Annals of internal medicine.

[46]  J. Hurley,et al.  Pulmonary oedema in rats given dehydromonocrotaline: A topographic and electron‐microscope study , 1975, The Journal of pathology.